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c-MYC stimulates cell proliferation through the suppression of cyclin-dependent
kinase (CDK) inhibitors including P15 (CDKN2B) and P21 (CDKN1A). It also activates
E-box-mediated transcription of various target genes including telomerase reverse
transcriptase (TERT) that is involved in cellular immortality and tumorigenesis. Trans-
forming growth factor-beta 1 (TGF-b1)-stimulated clone 22 (TSC-22/TSC22D1)
encodes a highly conserved leucine zipper protein that is induced by various stimuli,
including TGF-b. TSC-22 inhibits cell growth in mammalian cells and in Xenopus
embryos. However, underlying mechanisms of growth inhibition by TSC-22 remain
unclear. Here, we show that TSC-22 physically interacts with c-MYC to inhibit the
recruitment of c-MYC on the P15 (CDKN2B) and P21 (CDKN1A) promoters, effec-
tively inhibiting c-MYC-mediated suppression of P15 (CDKN2B) and also P21
(CDKN1A) promoter activities. In contrast, TSC-22 enhances c-MYC-mediated acti-
vation of the TERT promoter. Additionally, the expression of TSC-22 in embryonic
stem cells inhibits cell growth without affecting its pluripotency-related gene
expression. These results indicate that TSC-22 differentially regulates c-MYC-
mediated transcriptional activity to regulate cell proliferation.
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1 | INTRODUCTION
MYC is a proto-oncogene that encodes a basic helix-loop-helix leu-
cine zipper (bHLH-LZ) transcriptional factor named c-MYC. Overex-
pression of c-MYC and MYC family proteins has been detected in
numerous human cancers, including Burkitt’s lymphoma (c-MYC),
neuroblastoma (N-MYC), and small cell lung cancer (L-MYC).1-3 MYC
is an early response gene that is activated in response to mitogenic
signals4 and has a short half-life with tight transcriptional, post-tran-
scriptional, and post-translational controls.4-6
c-MYC dimerizes with MAX, and the c-MYC-MAX heterodimer
can activate various genes by directly binding to a specific DNA
sequence, termed E-box (50-CACGTG-30).7 E-boxes are found in the
promoters of a large group of c-MYC-induced genes that also
include protein-coding genes (eg telomerase reverse transcriptase
Abbreviations: bHLH-LZ, basic helix-loop-helix leucine zipper; CDK, cyclin-dependent
kinase; ID2, inhibitor of DNA binding 2; LIF, leukemia inhibitory factor; TERT, telomerase
reverse transcriptase; TSC-22, transforming growth factor-b1-stimulated clone 22.
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[TERT], cyclin D2 [CCND2], and ribosomal RNA genes).8-10 In con-
trast, c-MYC can repress various genes, including cyclin-dependent
kinase inhibitors such as P15 (CDKN2B) and P21 (CDKN1A),11,12
through its interaction with the zinc finger protein MIZ-1 at the ini-
tiator elements of their promoters.11,13 c-MYC-mediated transcrip-
tional activation or repression of the target genes influences many
biological processes, including the promotion of cell proliferation,
immortalization, inhibition of terminal differentiation, and induction
of apoptosis.
Transforming growth factor-beta 1 (TGF-b1)-stimulated clone 22
(TSC-22/TSC22D1) was first identified as a target gene of TGF-b1 in
mouse osteosarcoma cells.14 TSC-22 and TSC-22 family members
(KIAA0669/TSC22D2, GILZ/TSC22D3, and THG-1/TSC22D4) have a
conserved TSC-box and a leucine zipper domain.15 These proteins
form homo- or heterodimers with other family members. During
mouse embryogenesis, TSC-22 is expressed at the site of epithelial-
mesenchymal interaction16 and has transcriptional repressor activity
when fused to a heterologous DNA-binding domain.15 The expres-
sion of TSC-22 in cultured cells or in Xenopus embryo inhibits cellu-
lar proliferation.17,18 However, the mechanism of growth inhibition
by TSC-22 has not been determined. During our trial to elucidate
the mechanism of TSC-22, we found that TSC-22 bound to c-MYC.
In the present study, we investigated the regulation of c-MYC
transcriptional activity by TSC-22 and showed the mechanism of
growth inhibition by TSC-22.
2 | MATERIALS AND METHODS
2.1 | Cell culture
HEK293T cells and HaCaT cells were obtained from the ATCC
and Dr N.E. Fusenig, respectively. These were cultured in DMEM
(Sigma Chemical Co., St Louis, MO, USA) supplemented with 10%
FBS, penicillin G (100 U/mL), and streptomycin sulfate (0.1 mg/
mL; Wako Pure Chemical Industries, Ltd, Osaka, Japan). HaCaT
cells stably expressing FLAG-TSC-22 were maintained in culture
medium supplemented with 1 lg/mL puromycin (Sigma). MGZ5 ES
cells were maintained on feeder-free, gelatin-coated plates in leu-
kemia inhibitory factor (LIF)-supplemented medium as described
previously.19
2.2 | DNA constructs
c-MYC cDNA was provided by Drs B. Blackwood and R.N. Eisen-
man. Expression constructs pcDNA3-c-MYC and pcDNA3-FLAG-
inhibitor of DNA binding 2 (ID2) were described previously.20,21 Dr
M. Eilers provided cDNA for MIZ-1, which we cloned into pcDEF3.
TSC-22 cDNA from HaCaT cells was cloned into both pcDNA3 and
pCAGIP (for transfection into ES cells) vectors. c-MYC, TSC-22 dele-
tion and 4LA (L77A, L84A, L91A, and L98A) mutants were generated
using PCR. The P21 promoter WWP-luc,22 P15-luc,23 and pGL3-
EBox2-luc8 were provided by Drs B. Vogelstein, X.F. Wang, and R.
Dalla-Favera, respectively. These constructs were transfected into
cells using the FuGENE6 reagent (Promega, Madison, WI, USA)
according to the manufacturer’s recommendations.
2.3 | Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were solubilized in a lysis buffer con-
taining Tris-HCl (20 mmol/L, pH 7.5), NaCl (150 mmol/L), Nonidet P-
40 (1%), Trasylol (1.5%), and PMSF (1 mmol/L). After clearing by cen-
trifugation, total cell lysates or immunoprecipitates obtained using
the indicated antibodies were subjected to SDS-PAGE. Proteins were
electrotransferred onto PVDF membranes (Millipore, Burlington, MA,
USA) and subjected to immunoblotting. We used anti-c-MYC (9E10;
Santa Cruz Technology, Santa Cruz, CA, USA), FLAG (M2; Sigma),
TSC-22 (Abnova, Taipei, Taiwan), and a-TUBULIN (Millipore, Burling-
ton, MA, USA) antibodies as primary antibodies for immunoblotting.
Reacted antibodies were detected using an enhanced chemilumines-
cence detection system (GE Healthcare, Little Chalfont, UK). For re-
blotting, we stripped the membranes according to the manufacturer’s
protocol.
2.4 | Cell proliferation assay
HaCaT cells and their derivatives were seeded into 12-well plates at a
density of 1 9 104 cells per well and cultured for the indicated time
periods. Number of cells was counted using a hematocytometer. MGZ5
ES cells were transfected with pCAGIP-empty, FLAG-TSC-22, and
FLAG-ID2. After 24 hours, cells were trypsinized and equal numbers of
cells were seeded on gelatin-coated 6-cm plates and cultured for 6 days
in a feeder-free and LIF-supplemented medium. After photographing the
colonies under a phase-contrast microscope (Olympus, Tokyo, Japan),
cells were stained with crystal violet and colony numbers were measured
with image analysis software (Image J; NIH, Bethesda, MD, USA).
2.5 | Luciferase assay
We transfected the cells using FuGENE6 transfection reagent (Pro-
mega, Madison, WI, USA) according to the manufacturer’s recom-
mendations. Luciferase activity in the cell lysates was determined by
a luciferase reporter assay system (Promega, Madison, WI, USA)
using a luminometer (AutoLumat LB953; EG & G Berthold, Bad
Wildbad, Germany). Luciferase activities were normalized to b-galac-
tosidase activity of cotransfected CH110 (GE Healthcare).
2.6 | Chromatin immunoprecipitation
ChIP was carried out as described previously,24 with some modifica-
tions. Cells were treated with 1% formaldehyde at 37°C for 20 min-
utes and washed twice with PBS. The cells were resuspended in
3 mL TE buffer supplemented with PMSF (1 mmol/L) and sonicated.
Soluble chromatin was collected by centrifugation for 10 minutes at
16 000 9 g in a microfuge and adjusted to 0.1% SDS, 1% Triton
X-100, 0.1% sodium deoxycholate, and 140 mmol/L NaCl. Immuno-
precipitation reactions containing 1 mL chromatin solution, 25 lL
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protein A-Sepharose beads, and 1 lg control IgG or anti-c-MYC anti-
body (N262; Santa Cruz) were incubated with end-over-end rotation
overnight at 4°C. The immunoprecipitates were washed sequentially
four times with RIPA buffer containing NaCl (0.3 mol/L), once with
RIPA buffer containing no NaCl, and once with TE. DNA was then
eluted with elution buffer (10 mmol/L DTT, 1% SDS, and 0.1 mol/L
NaHCO3). Following reverse-cross-linking at 65°C for 6 hours, DNA
was treated with proteinase K and purified using a PCR purification
kit (Qiagen, Hilden, Germany). DNA was eluted into 20 lL (immuno-
precipitates) and 50 lL (input) of elution buffer, and 1 lL of this
solution was used for PCR analysis using the PCR primers listed in
Table S1.
2.7 | Reverse transcription-PCR
Total RNA was isolated using ISOGEN II (Nippon Gene, Tokyo,
Japan). RT was carried out using High Capacity RNA-to-cDNA Mas-
ter Mix (Applied Biosystems, Foster City, CA, USA) and PCR was
done using Ex Taq polymerase (TaKaRa Bio Inc., Shiga, Japan). PCR
primers are listed in Table S2.
2.8 | Immunofluorescence
Immunofluorescence in HaCaT cells stably expressing TSC-22 was
carried out using anti-TSC-22 and anti-c-MYC (N262; Santa Cruz)
primary antibodies followed by incubation with Alexa 488-labeled
goat anti-mouse IgG and Texas Red-labeled goat anti-rabbit IgG sec-
ondaries (Molecular Probes, Eugene, OR, USA). Nuclei were stained
with Hoechst 33342 (Sigma). Intracellular localization of TSC-22 and
c-MYC was observed using a fluorescence microscope (Axiovert
200; Carl Zeiss AG, Oberkochen, Germany).
2.9 | Statistical analysis
Statistical analyses of the data was carried out with the t test using
a statistics function in Microsoft Excel (Microsoft, Redmond, WA,
USA) or Prism 5 (Graphpad Software, La jolla, CA, USA). Probability
values <.05 were considered significant and indicated as *P < .05,
**P < .01.
3 | RESULTS
3.1 | TSC-22 overexpressing cells form smaller
colonies
To investigate the function of TSC-22 in cell proliferation, we
generated HaCaT human keratinocyte cells stably expressing TSC-
22 (Figure 1A). HaCaT cells expressing TSC-22 (clone #11 and
#17) exhibited slower proliferation than Mock-transfected cells
(Figure 1B). We also examined the effects of TSC-22 on the
colony formation of mouse ES (MGZ5) cells. MGZ5 cells were
transfected with TSC-22 or ID2 overexpression plasmids and the
transfected cells were selected using puromycin for 6 days
(Figure S1A). We used ID2 as a reference because ID2 suppresses
ES cell differentiation and sustains self-renewal,25 and also
regulates MYC-mediated tumorigenesis.26 Using this experimental
procedure, we can assess clonal propagation of ES cells only if
they maintain their pluripotency.27 Compared with Mock- or ID2-
transfected cells, TSC-22-transfected cells formed smaller colonies
but kept an undifferentiated morphology (Figure 1C,D). However,
the total number of colonies in Mock-, TSC-22-, and ID2-trans-
fected cells was similar (Figure 1E). The expression of c-MYC pro-
tein and undifferentiated markers (Nanog, Oct4, and Rex1 mRNA)
F IGURE 1 TSC-22 inhibits cell
proliferation. A, Immunoblot analysis
showing expression of TSC-22, c-MYC,
and a-TUBULIN in FLAG-TSC-22-
expressing HaCaT cells (clones #11 and
#17), as indicated. B, Cell growth of Mock
and FLAG-TSC-22-expressing HaCaT cells
(clones #11 and #17). Mean  SD, n = 3.
*P < .05, **P < .01 (on days 5 and 6). C-E,
Mouse ES cells (MGZ5 cells) were
transfected with Mock, FLAG-TSC-22, and
FLAG-ID2 expression plasmids, as
indicated, transferred to 6-cm dishes and
cultured for 6 d in the presence of
puromycin. C, Morphology of colonies
transfected with Mock, FLAG-TSC-22, and
FLAG-ID2 cDNAs, as indicated. D, Whole
view of the colonies in 6-cm dishes stained
with crystal violet. E, Number of colonies.
Mean  SD. n = 3
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F IGURE 2 TSC-22 interacts with c-MYC in HaCaT cells. A, Interaction of TSC-22 and c-MYC in Mock- and FLAG-TSC-22-expressing
HaCaT cells (clone #17). Cell lysates were immunoprecipitated with anti-FLAG antibody (IP), followed by immunoblotting using
antibodies as indicated (Blot). IgG (H), immunoglobulin heavy chain used for IP. B, Localization of TSC-22 in FLAG-TSC-22-expressing
HaCaT cells (clone #17). Cells were cultured on coverslips and stained with anti-TSC-22 and c-MYC antibodies. Nuclei were
counterstained with DAPI
F IGURE 3 Effects of TSC-22 on c-
MYC-mediated transcriptional activation
and repression. A, ChIP analysis of c-MYC
binding to the P15, P21, and TERT
promoters in Mock- and FLAG-TSC-22-
expressing HaCaT cells (clone #17).
Control IgG was used as a negative
control. B-D, 293T cells were transfected
with the luciferase reporter constructs; (B)
P15 (CDKN2B)-luc, (C) WWP (CDKN1A)-
luc, and (D) hTERT E-box2-luc, along with
various combinations of c-MYC and TSC-
22 expression plasmids, and luciferase
activity was measured. Mean  SD. n = 3.
E, Expression of P15, P21, and TERT
mRNA in Mock- and FLAG-TSC-22-
expressing HaCaT cells (clone #11 and
#17). b-actin was used as a loading control
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was similarly maintained in Mock-, TSC-22-, and ID2-transfected
cells (Figure S1B). As colony numbers and morphology were simi-
lar across groups, these data lead to the conclusion that TSC-22
specifically affects proliferation and not other differentiation
parameters.
3.2 | TSC-22 interacts with c-MYC
Next, we verified the interaction between transfected TSC-22 and
endogenous c-MYC. Immunoprecipitation analysis clearly showed
the interaction between FLAG-TSC-22 and c-MYC (Figure 2A) and,
furthermore, TSC-22, which is distributed mainly in nuclei, co-loca-
lized with c-MYC in the nucleus (Figure 2B).
3.3 | TSC-22 cancels c-MYC-mediated suppression
of P15 (CDKN2B) and P21 (CDKN1A) and enhances c-
MYC-mediated activation of TERT
c-MYC is known to stimulate cell growth through transcriptional
downregulation of CDK inhibitors, including P15 and P21.11,12 We
therefore investigated the binding of c-MYC to the P15 (CDKN2B,
101 to +44), P21 (CDKN1A, 152 to 12), and TERT (204 to
+53) promoters using chromatin immunoprecipitation. Recruitment
of c-MYC was reduced on the P15 and P21 promoters but enhanced
on the TERT promoter in TSC-22-transfected HaCaT cells (Figure 3A)
and, as shown in Figure 3B,C, c-MYC suppressed the transcriptional
activity of the P15 and P21 promoters (P15-luc and WWP-luc,
F IGURE 4 Domains required for TSC-22 and c-MYC interaction. A,C,D,E, 293T cells were transfected with expression plasmids, as
indicated. Cell lysates were immunoprecipitated with anti-FLAG antibody (IP), followed by immunoblotting using antibodies as indicated (Blot).
A, Leucine zipper domain (LZ) of c-MYC is required for TSC-22 and c-MYC interaction. IgG (H), IgG heavy chain used for IP. B, Schematic
representation of the structures of TSC-22 wild-type (WT), deletion mutants of leucine zipper domain (DLZ), TGF-b1 stimulated clone 22 box
(DTSC), N-terminal part (DN), C-terminal part (DC), and four leucine-to-alanine mutations in the LZ domain (4LA). C, Interaction of c-MYC and
WT or deletion mutants of TSC-22. N-terminal part and LZ domain of TSC-22 are required for TSC-22-c-MYC interaction. D, Homodimer
formation of FLAG-TSC-22 WT and HA-TSC-22 WT or HA-TSC-22 4LA, as indicated. E, Heterodimer formation of HA-c-MYC and FLAG-TSC-
22 WT or FLAG-TSC-22 4LA, as indicated. F, P15-luc activity suppressive effects of c-MYC are canceled by TSC-22 WT but not by TSC-22
DLZ. 293T cells were transfected with the luciferase construct P15 (CDKN2B)-luc along with various combinations of the indicated expression
plasmids, and luciferase activity was measured. Mean  SD. n = 3. *P < .05, **P < .01
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respectively). Importantly, TSC-22 canceled c-MYC-mediated sup-
pression of P15 and P21 in an expression level-dependent way. Fur-
thermore, TSC-22 stimulated P15 and P21 promoter activity in the
absence of c-MYC transfection, suggesting that TSC-22 inhibits
endogenous c-MYC activity. Next, we investigated the effect of
TSC-22 on c-MYC-mediated promoter activation by using the TERT
promoter luciferase construct (pGL3-EBox2-luc), which contains two
E-boxes that are activated by c-MYC.8 As shown in Figure 3D, TSC-
22 stimulated c-MYC-mediated activation of the TERT promoter but
showed no activity in the absence of c-MYC coexpression. Corre-
sponding to these reporter results, the amount of endogenous
mRNA of P15, P21, and TERT was increased in HaCaT cells stably
expressing TSC-22 (Figure 3E).
3.4 | LZ and N-terminal domains are required for
c-MYC and TSC-22 interaction
The c-MYC family proteins possess the bHLH-LZ domain at their
C-terminal.28 We examined the bHLH-LZ domain of c-MYC for its
role in the interaction with TSC-22. As shown in Figure 4A, c-MYC
ΔLZ, without the LZ domain, did not interact with TSC-22. Further-
more, we constructed TSC-22 mutants (Figure 4B) and examined
their interactions with c-MYC, finding that TSC-22 ΔN, without the
43 N-terminal amino acids, completely lost interaction with c-MYC
(Figure 4C, lane 5) and the interaction between TSC-22 ΔLZ and c-
MYC was significantly reduced (Figure 4C, lane 3). As TSC-22 family
members are known to form homo- or heterodimers through their
LZ domains, we then constructed TSC-22 4LA, which has four leu-
cine-to-alanine mutations in the LZ domain (L77A, L84A, L91A and
L98A), and examined the role in homodimer formation and interac-
tion with c-MYC. As shown in Figure 4D,E, TSC-22 4LA lost
homodimer formation and heterodimer formation with c-MYC.
These results suggested that the N-terminal domain (amino acids: 1-
43) and LZ domain of TSC-22 are involved in the interaction with
c-MYC. Finally, we examined the role of interaction between
c-MYC and TSC-22 for the regulation of P15 promoter activity. As
shown in Figure 4F, TSC-22 ΔLZ was unable to inhibit c-MYC-
mediated suppression of the P15 promoter activity. These results
indicated that the interaction between TSC-22 and c-MYC is essen-
tial for the inhibition of c-MYC-mediated suppression of the P15
promoter activity.
3.5 | TSC-22 enhances c-MYC-MAX but suppresses
c-MYC-MIZ-1 heterodimer formation
Reports have shown c-MYC to activate or repress various genes
through interaction with MAX and MIZ-1, respectively.8-10,12,13 We
examined the interaction of these proteins with TSC-22 by immuno-
precipitation. As shown in Figure 5A, TSC-22 bound to c-MYC, but
not to MAX and MIZ-1. We next examined the effect of TSC-22 in
c-MYC-MAX and c-MYC-MIZ-1 heterodimer formation. As shown in
Figure 5B,C, the interaction between c-MYC and MAX was
enhanced in the presence of TSC-22 (Figure 5B, lanes 2 and 3).
However, the interaction between c-MYC and TSC-22 was reduced
F IGURE 5 Effects of TSC-22 on c-
MYC-MAX and c-MYC-MIZ-1 heterodimer
formation. A-C, 293T cells were
transfected with expression plasmids, as
indicated. Cell lysates were
immunoprecipitated with anti-FLAG
antibody (IP), followed by immunoblotting
using antibodies as indicated (Blot). IgG (H)
and IgG (L), IgG heavy chain and light
chain used for IP, respectively. A,
Interaction of TSC-22 with c-MYC but not
with MIZ-1 and MAX. B, TSC-22 enhances
c-MYC-MAX interaction and MAX
competes with TSC-22 for c-MYC binding.
C, TSC-22 suppresses c-MYC-MIZ-1
interaction
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in the presence of MAX (Figure 5B, lanes 3 and 4). In contrast, TSC-
22 interaction to c-MYC suppressed c-MYC-MIZ-1 interaction (Fig-
ure 5C, lanes 3 and 4). These results suggested that TSC-22 binds to
c-MYC and enhances the c-MYC-MAX heterodimer formation after
only transient involvement, but suppresses the c-MYC-MIZ-1 het-
erodimer formation.
4 | DISCUSSION
In the present study, we showed that TSC-22 regulates transcrip-
tional activity of c-MYC by interaction with the c-MYC LZ domain
and differentially affecting c-MYC-MAX and c-MYC-MIZ-1 heterodi-
mer formation. Correspondingly, TSC-22 inhibited c-MYC recruit-
ment to the P15 and P21 promoters (Figure 3A) and canceled c-
MYC-mediated suppression of P15 and P21 (Figure 3B,C). In con-
trast, TSC-22 enhanced c-MYC recruitment to the TERT promoter
and promoted c-MYC-mediated transcriptional activation of the
TERT promoter (Figure 3A,D).
The X-ray structure of the MYC-MAX-DNA (E-box) complex
shows that the MYC-MAX heterodimer dimerizes to form a large
heterotetramer, which allows MYC to upregulate expression of the
target genes even if their promoters have widely separated E-
boxes.29 We observed that TSC-22 enhances MYC-MAX dimer
formation (Figure 5B), raising the possibility that TSC-22 enhances
the c-MYC-induced activation of TERT expression by enhancing
MYC-MAX interaction to the E-box (Figure 3A,D,E). In contrast,
the formation of MYC-MIZ1 on the P15 and P21 promoters may
be impaired by the suppression of MYC-MIZ-1 heterodimer
formation (Figures 3A and 5C). Further global genomic analyses of
c-MYC-MAX and c-MYC-MIZ-1 target genes would help to under-
stand the likely mechanism of action and further functions of
TSC-22.
Several studies have reported downregulation of TSC-22 in
tumors, including those found in the salivary gland, brain, and pros-
tate.18,30,31 Furthermore, TSC22D1 is hypermethylated and silenced
in T-cell- or natural killer-large granular lymphocyte leukemia, and
Tsc-22-deficient mice are susceptible to tumorigenesis in a carcino-
gen-induced mouse liver-tumor model by the ablation of a RAF
interacting Tsc-22 that negatively regulates RAS-mediated transfor-
mation.32,33 Our current results indicated further function of TSC-22
as a tumor suppressor protein through binding to c-MYC. Our
current findings provide a novel TGF-b-induced-TSC-22-mediated
regulatory network to the canonical c-MYC function.33
We verified the effect of Tsc-22 on the clonal propagation of
mouse ES cells. As shown in Figures 1C,D and S1B, Tsc-22 inhib-
ited ES cell colony growth without affecting pluripotency-related
gene expression. A growing amount of evidence suggests that the
dormancy of tissue stem cells plays a critical role not only in stem
cell maintenance but also in the properties of cancer stem cells,
including resistance to therapy and cancer relapse.34 In the mouse
leukemia model described earlier, the recovery of TSC-22 expres-
sion increased the survival of mice with leukemia.32 Furthermore,
targeted disruption of Tsc22d1 in mice enhanced the proliferation
and in vivo repopulation efficiency of hematopoietic precursor
cells.32 The results of the current study provide novel insights into
the potential roles of TSC-22 in stem cell dormancy through the
modification of c-MYC-mediated transcriptional regulation to
enhance P15, P21 and TERT expression. Further studies are there-
fore needed to understand the regulation of stem cell dormancy
by TSC-22.
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